The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine

Thromb Haemost. 2012 Sep;108(3):586-8. doi: 10.1160/TH12-04-0222. Epub 2012 Jul 10.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antithrombins / adverse effects*
  • Antithrombins / blood
  • Antithrombins / pharmacology
  • Benzimidazoles / adverse effects*
  • Benzimidazoles / blood
  • Benzimidazoles / pharmacology
  • Blood Coagulation / drug effects
  • Blood Coagulation Factors / pharmacology
  • Dabigatran
  • Drug Evaluation, Preclinical
  • Drug Monitoring / methods*
  • Factor VIIa / pharmacology
  • Fibrin / biosynthesis
  • Hemorrhagic Disorders / blood
  • Hemorrhagic Disorders / chemically induced*
  • Humans
  • In Vitro Techniques
  • Point-of-Care Systems
  • Pyridines / adverse effects*
  • Pyridines / blood
  • Pyridines / pharmacology
  • Recombinant Proteins / pharmacology
  • Thrombelastography*
  • Thrombin / antagonists & inhibitors
  • Whole Blood Coagulation Time

Substances

  • Antithrombins
  • Benzimidazoles
  • Blood Coagulation Factors
  • Pyridines
  • Recombinant Proteins
  • prothrombin complex concentrates
  • Fibrin
  • recombinant FVIIa
  • Factor VIIa
  • Thrombin
  • Dabigatran